Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QBKPN - Qu Biologics

Next Previous
X
Search
Drug Profile

QBKPN - Qu Biologics

Alternative Names: Lung targeted site specific immunomodulator - Qu Biologics; QBKPN SSI

Latest Information Update: 03 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qu Biologics
  • Developer National Research Council Canada; Qu Biologics
  • Class Antineoplastics; Bacterial antigens; Cancer vaccines; COVID-19 vaccines; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Immunodeficiency disorders; Non-small cell lung cancer
  • Phase I Asthma; Chronic obstructive pulmonary disease
  • Preclinical COVID 2019 infections

Most Recent Events

  • 03 Jan 2024 Phase-I clinical trials in Asthma (SC), prior to January 2023 (Qu Biologics pipeline, January 2024)
  • 03 Jan 2024 Phase-I clinical trials in Chronic obstructive pulmonary disease (SC), prior to January 2023 (Qu Biologics pipeline, January 2024)
  • 17 Oct 2022 Qu Biologics plans the phase II RESILIENCE trial in Immunodeficiency disorders in Canada in 4Q 2022 (SC, Injection) (NCT05421325)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top